Medical Marijuana and Insurance Coverage: What Is and Isn't Covered
Federal Schedule I classification creates an almost paradoxical situation for patients: a treatment recommended by licensed physicians in 38 states (plus Washington D.C.) remains categorically excluded from virtually every major insurance reimbursement pathway. This page maps the coverage landscape — what federal law prohibits, what narrow exceptions exist, and how state-level programs have begun filling some of the gap.
Definition and scope
Insurance coverage for medical marijuana means any arrangement in which a third-party payer — a private health insurer, a government health program like Medicaid or Medicare, or a workers' compensation carrier — reimburses patients for the cost of cannabis products recommended by a licensed physician.
The short version: that reimbursement essentially does not exist in the United States at the federal level. The Drug Enforcement Administration classifies marijuana as a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 812), a category defined by "no currently accepted medical use." As long as that classification holds, federal programs cannot fund it, and private insurers operating under federal law treat it as a non-covered substance. The full picture of that federal-state tension is detailed at the regulatory context for medical marijuana page.
For patients tracking their spending, the practical consequence is that cannabis purchases come entirely out-of-pocket — and costs are not trivial. The medical marijuana cost and affordability overview on this site explores patient spending patterns in more depth.
How it works
Understanding why coverage doesn't exist requires a quick look at how reimbursement actually gets approved.
For a treatment to qualify for insurance reimbursement, it typically needs:
- FDA approval — indicating the agency reviewed clinical evidence and found the drug safe and effective for a specific indication
- A procedure or drug code — the standardized billing systems (ICD-10-CM, CPT, NDC codes) that insurers use to process claims
- A payer policy — an explicit determination by the insurer or government program that the treatment is medically necessary and covered
Cannabis products dispensed through state programs fail all three tests simultaneously. The FDA has not approved smoked, vaped, or edible cannabis for any condition. No National Drug Code covers dispensary products as standardized pharmaceuticals. And no major private or public payer has issued a reimbursement policy covering them.
The FDA has approved three cannabis-derived or cannabis-related medications through the standard drug approval process: dronabinol (Marinol, Syndros), nabilone (Cesamet), and cannabidiol (Epidiolex). These carry standard NDC codes, can be prescribed on a standard prescription pad, and are eligible for pharmacy benefit coverage. Epidiolex, approved in 2018 for two severe epilepsy syndromes, is covered by Medicaid in most states and by most major private insurers — a sharp contrast to dispensary-purchased CBD products, which are not. The FDA-approved cannabis-based medications page covers those distinctions in detail.
Common scenarios
Private health insurance: Major carriers including Anthem, UnitedHealth, Cigna, and Aetna uniformly exclude medical marijuana from coverage as a non-FDA-approved substance. Patients may still be reimbursed for a physician consultation that results in a cannabis recommendation, since the visit itself is a billable medical service — the product is not.
Medicare: Medicare Part D covers prescription drugs approved by the FDA. Because dispensary cannabis has no FDA approval, it is excluded. The Centers for Medicare & Medicaid Services (CMS) has issued no coverage determination that would change this.
Medicaid: Medicaid is jointly funded by federal and state governments. Federal Medicaid dollars cannot be used for Schedule I substances, per 42 C.F.R. § 440.120 and related guidance. A handful of states — New Mexico being the most cited example — have explored or implemented limited state-funded reimbursement programs using state-only funds, specifically designed to avoid triggering the federal funding prohibition.
Workers' compensation: This is where the picture gets genuinely complicated. Workers' compensation is regulated state by state, and at least 10 states have had court decisions or statutory changes requiring employers or their insurers to reimburse injured workers for medical marijuana costs in specific circumstances, according to analysis published by the National Conference of State Legislatures (NCSL). New Mexico, New York, New Hampshire, and New Jersey are among the states where courts have issued such rulings. The outcomes turn on whether the state's workers' comp statute treats cannabis as a "reasonable and necessary" medical expense, and whether federal law preempts state mandates — a question courts have answered inconsistently.
Veterans Affairs (VA): The VA does not prescribe, pay for, or help veterans obtain marijuana. VA clinicians can discuss cannabis with patients under a 2017 policy update, and veterans enrolled in VA health care will not lose benefits for state-legal marijuana use — but the VA provides no coverage for dispensary purchases (VA Directive 2011-004, updated guidance 2017).
Decision boundaries
The dividing line that determines coverage eligibility runs along two axes:
FDA approval status — The three approved cannabinoid medications are insurable through standard channels. Dispensary products are not, regardless of the condition being treated.
Funding source — State programs using exclusively state appropriations have more flexibility than programs that draw federal dollars. This is why state workers' comp systems can sometimes require reimbursement while federal programs cannot.
A useful contrast: a patient prescribed Epidiolex for Dravet syndrome may pay a standard specialty copay. A patient purchasing cannabis flower at a dispensary for chronic pain under a physician's recommendation pays full retail with no offset, even in a state where that purchase is fully legal and medically endorsed.
The emerging middle ground involves medical marijuana patient rights litigation and state legislative action — the trajectory is toward incremental state-level coverage mandates, not federal reform, at least for the foreseeable horizon.